logo

EDSA

Edesa Biotech·NASDAQ
--
--(--)
--
--(--)
2.16 / 10
Underperform

EDSA's fundamental score is 2.2 out of 10, indicating subpar quality. Key weaknesses include a low Net profit / Total profit ratio (0/10) and negative Asset-MV (value -0.5007, group 3). Strengths such as high Profit-MV (2/10) and Cash-MV (2/10) are offset by these critical deficits, suggesting ongoing operational and profitability concerns.

Fundamental(2.16)SentimentTechnical

Analysis Checks(5/10)

Revenue-MV
Value-0.26
Score1/3
Weight12.12%
1M Return5.20%
Inventory turnover ratio
Value111.00
Score3/3
Weight10.65%
1M Return5.26%
Gross profit margin (%)
Value48.17
Score1/3
Weight-0.94%
1M Return-0.54%
Profit-MV
Value0.46
Score2/3
Weight18.14%
1M Return7.79%
PB-ROE
Value0.23
Score1/3
Weight16.75%
1M Return7.02%
Current assets turnover ratio
Value2.56
Score2/3
Weight2.12%
1M Return1.15%
Fixed assets turnover ratio
Value28052.73
Score3/3
Weight1.55%
1M Return0.86%
Asset-MV
Value-0.50
Score1/3
Weight21.99%
1M Return8.74%
Cash-MV
Value-0.07
Score2/3
Weight18.16%
1M Return7.73%
Net profit / Total profit (%)
Value100.01
Score0/3
Weight-0.54%
1M Return-0.30%
Is EDSA fundamentally strong?
  • EDSA scores 2.16/10 on fundamentals and holds a Premium valuation at present. Backed by its -99.57% ROE, 0.00% net margin, -1.30 P/E ratio, 0.75 P/B ratio, and 34.20% earnings growth, these metrics solidify its Underperform investment rating.